Pharmafile - Research and Development News
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent...
-Samsung BioLogics delisted from Korean Stock Exchange-No-deal prep a waste of time, Welsh ABPI says -Alabama insurer won't cover oxycontin -NICE say...
MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or metastatic...
The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a 585 page...
To mark this year’s World Diabetes Day on 14 November, a new report has shed more light on the psychological impact of type 1 and 2 diabetes,...
Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of healthcare in Germany.
The outbreak of Ebola in the Democratic Republic of Congo (DRC) is expected to last until mid-2019, a World Health Organization (WHO) official has...
Britain uses more than twice as many antibiotics as the Netherlands, according to a new report published by the World Health Organization (WHO).
South Korean firm Samsung BioLogics has been delisted from the South Korean stock exchange.
Novartis has declared new findings for Entresto, showing that the drug proved itself superior to enalapril-a in patients with heart failure with...
